Gilder Gagnon Howe & CO LLC Madrigal Pharmaceuticals, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $7.87 Billion
- Q3 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 38,133 shares of MDGL stock, worth $13 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
38,133
Previous 38,377
0.64%
Holding current value
$13 Million
Previous $10.8 Million
24.73%
% of portfolio
0.1%
Previous 0.14%
Shares
3 transactions
Others Institutions Holding MDGL
# of Institutions
295Shares Held
22MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$843 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$695 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$690 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$678 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$672 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.82B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...